일반의약품(OTC) 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Over the Counter Drugs Market was valued at USD 180 billion in 2024 and is projected to expand at a 5.4% CAGR between 2025 and 2034, driven largely by a rising consumer preference for self-medication and increasing demand for accessible healthcare solutions. As consumers become more health-conscious and proactive in managing minor ailments, OTC drugs are quickly emerging as a go-to solution for quick relief and cost-effective treatment options. The widespread availability of OTC products in pharmacies, supermarkets, online platforms, and convenience stores is making it easier for consumers to access essential medications without a prescription. In addition, ongoing advancements in drug formulations, such as fast-dissolving tablets and flavored syrups, are enhancing user convenience and compliance, fueling market growth even further.

Regulatory bodies across the globe are also playing a crucial role by ensuring stringent quality checks and guidelines, which boost consumer confidence in using OTC medications for everyday health concerns. As healthcare costs continue to rise, many individuals are opting for OTC options to manage common conditions like pain, colds, digestive issues, and skin irritations without the need for physician visits, thereby contributing to overall market expansion. Furthermore, an aging population seeking easy and affordable solutions for recurring issues like joint pain, digestive discomfort, and sleep disorders is supporting long-term demand for OTC products. The growing trend toward preventive healthcare and wellness supplements is also influencing consumer purchasing behavior, with many people adopting vitamins, minerals, and herbal supplements as part of their daily routines to maintain health and well-being.

OTC drugs, which do not require a doctor's prescription, are carefully regulated by health authorities to ensure their safety, efficacy, and quality. These medications are available in diverse forms, such as tablets, ointments, sprays, and solutions, offering users convenient options for managing common health issues at home. The market is segmented into various categories, including cold and cough remedies, vitamins and supplements, digestive aids, skin treatments, pain relievers, sleeping aids, and others. Among these, cold and cough remedies generated USD 45.2 billion in 2024, as the rising incidence of respiratory illnesses like colds and flu, particularly during seasonal transitions, drives demand for quick-relief products such as decongestants and cough syrups.

When looking at product formulation, tablets dominated the OTC market with USD 85.9 billion in 2024, as they remain the preferred choice due to precise dosing, convenience, and ease of use for treating conditions such as pain, respiratory issues, and other acute ailments. The consistent launch of new tablet-based OTC products continues to boost their market share.

In regional analysis, the U.S. OTC Drugs Market accounted for USD 42.4 billion in 2024 and is anticipated to grow at a 4.8% CAGR through 2034. The country's robust pharmaceutical landscape, significant R&D investments, and rising consumer inclination toward self-care are propelling market growth alongside growing awareness around early treatment and preventive healthcare solutions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing consumer awareness for self-medication and disease management
    • 3.2.1.2 High cost of prescription drugs leading to shift towards OTC drugs
    • 3.2.1.3 Favorable regulatory support for OTC drug approvals
    • 3.2.1.4 Expanding product accessibility
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Concern towards misuse or drug abuse
    • 3.2.2.2 Potential side effects and interactions due to medication
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Prescription to nonprescription switch list
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Category, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Cold and cough remedies
• 5.3 Vitamins and supplements
• 5.4 Digestive and intestinal remedies
• 5.5 Skin treatment
• 5.6 Analgesics
• 5.7 Sleeping aids
• 5.8 Other drug categories

Chapter 6 Market Estimates and Forecast, By Formulation Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Tablets
• 6.3 Liquids
• 6.4 Ointments
• 6.5 Sprays

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Online channels
• 7.3 Offline channels
  • 7.3.1 Hospital pharmacies
  • 7.3.2 Retail pharmacies
  • 7.3.3 Other offline channels

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 Alkem Laboratories
• 9.3 Aytu Biopharma (Aytu Consumer Health)
• 9.4 Bayer AG
• 9.5 Cipla
• 9.6 Dr. Reddy's Laboratories
• 9.7 GlaxoSmithKline Plc
• 9.8 Glenmark Pharmaceuticals
• 9.9 Haleon
• 9.10 Johnson & Johnson Services
• 9.11 Perrigo Company
• 9.12 Pfizer
• 9.13 Piramal Enterprises
• 9.14 Reckitt Benckiser Group
• 9.15 Sanofi
• 9.16 Sun Pharmaceuticals
• 9.17 Teva Pharmaceutical Industries
• 9.18 The Blackstone Group (Alinamin Pharmaceutical)
• 9.19 Viatris